Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Liang, Jian Fang ^a   Wang, Hong Kun ^a   Xiao, Hong ^a   Li, Ning ^a   Cheng, Cai Xia ^a   Zhao, Yu Ze ^a   Ma, Yan Bo ^a   Gao, Jian Zhong ^a   Bai, Rui Bing ^a   Zheng, Hui Xia ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; OSTEONECTIN; VASCULOTROPIN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER TISSUE; COLON ADENOCARCINOMA; COLON BIOPSY; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MICROVASCULATURE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; STROMA CELL; TUMOR DIFFERENTIATION; ADENOCARCINOMA; COLON TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MICROVESSELS; MIDDLE AGED; OSTEONECTIN; PROGNOSIS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953511554     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-71     Document Type: Article

References (36)

1. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. G Des Guetz B Uzzan P Nicolas M Cucherat JF Morere R Benamouzig JL Breau GY Perret, Br J Cancer 2006 94 1823 1832 10.1038/sj.bjc.6603176 16773076
2. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. AD Bradshaw EH Sage, J Clin Invest 2001 107 1049 54 10.1172/JCI12939 11342565
3. SPARC and tumor growth: where the seed meets the soil? PE Framson EH Sage, J Cell Biochem 2004 92 679 90 10.1002/jcb.20091 15211566
4. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. N Said K Motamed, Am J Pathol 2005 167 6 1739 52 16314484
5. Normalization of the ovarian cancer microenvironment by SPARC. N Said MJ Socha JJ Olearczyk AA Elmarakby JD Imig K Motamed, Mol Cancer Res 2007 5 1015 30 10.1158/1541-7786.MCR-07-0001 17951402
6. The extracellular glycoprotein SPARC interacts with platelet-derived growth factor(PDGF)-AB and-BB and inbibits the binding of PDGF to its receptors. EW Raines TF Lane ML Iruela-Arispe R Ross EH Sage, Proc Natl Acad Sci USA 1992 89 1281 5 10.1073/pnas.89.4.1281 1311092
7. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. F Ledda AI Bravo S Adris L Bover J Mordoh OL Podhajcer, J Invest Dermatol 1997 108 210 4 10.1111/1523-1747.ep12334263 9008236
8. SPARC antagonizes the effect of bFGF on the migration of bovine aortic endothelial cells. P Hasselaar EH Sage, J Cell Biochem 1992 49 272 83 10.1002/jcb.240490310 1644864
9. Altered cytoplasmic to nuclear ratio of survivin is a prognostic indicator in breast cancer. DJ Brennan E Rexhepaj SL O'Brien E McSherry DP O'Connor A Fagan AC Culhane DG Higgins K Jirstrom RC Millikan G Landberg MJ Duffy SM Hewitt WM Gallagher, Clin Cancer Res 2008 14 2681 9 10.1158/1078-0432.CCR-07-1760 18451232
10. Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. CL Koo LF Kok MY Lee TS Wu YW Cheng JD Hsu A Ruan KC Chao CP Han, J Transl Med 2009 7 25 10.1186/1479-5876-7- 25 19366452
11. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. S Zhou GP Wang C Liu M Zhou, BMC Cancer 2006 30 231 10.1186/1471-2407-6-231 (Pubitemid 44566740)
12. Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. J Gao A Knutsen G Arbman J Carstensen B Frånlund XF Sun, Dig Liver Dis 2009 41 2 116 22 Epub 2008 Nov 26 10.1016/j.dld.2008.07.315 19038587
13. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. H Huynh PK Chow N Palanisamy M Salto-Tellez BC Goh CK Lee A Somani HS Lee R Kalpana K Yu PH Tan J Wu R Soong MH Lee H Hor KC Soo HC Toh P Tan, J Hepatol 2008 49 52 60 10.1016/j.jhep.2008.02.022 18490075
14. Correlations between cyclooxygenase 2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. RH Nakamoto H Uetake S Iida YV Kolev LT Soumaoro Y Takagi M Yasuno K Sugihara, Jpn J Clin Oncol 2007 37 679 85 10.1093/jjco/hym080 17846040
15. SPARC in cancer biology: its role in cancer progression and potential for therapy. IT Tai MJ Tang, Drug Resist Updat 2008 11 231 46 10.1016/j.drup.2008. 08.005 18849185
16. SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. CL Haber V Gottifredi AS Llera E Salvatierra F Prada L Alonso EH Sage OL Podhajcer, Int J Cancer 2008 122 1465 75 10.1002/ijc.23216 18059024
17. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. PJ Barth R Moll A Ramaswamy, Virchows Arch 2005 446 532 6 10.1007/s00428-005-1256-9 15838642
18. The fibromatosis signature defines a robust stromal response in breast carcinoma. AH Beck I Espinosa CB Gilks M van de Rijn RB West, Lab Invest 2008 88 591 601 10.1038/labinvest.2008.31 18414401
19. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. A Bergamaschi E Tagliabue T Sørlie B Naume T Triulzi R Orlandi HG Russnes JM Nesland R Tammi P Auvinen VM Kosma S Ménard AL Børresen-Dale, J Pathol 2008 214 357 67 10.1002/path.2278 18044827
20. Animmune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. AE Teschendorff A Miremadi SE Pinder IO Ellis C Caldas, Genome Biol 2007 8 157 10.1186/gb-2007-8-8-r157 17683518
21. Protein 4.1B suppresses prostate cancer progression and metastasis. SY Wong H Haack JL Kissil M Barry RT Bronson SS Shen CA Whittaker D Crowley RO Hynes, Proc Natl Acad Sci USA 2007 104 12784 9 10.1073/pnas.0705499104 17640904
22. Analysis of the gene expression of SPARC and its prognostic value for bladder cance. M Yamanaka K Kanda NC Li T Fukumori N Oka HO Kanayama S Kagawa, J Urol 2001 166 2495 9 10.1016/S0022-5347(05)65623-6 11696817
23. Enhanced Expression of SPARC/Osteonectin in the Tumor associated Stroma of Non Small Cell Lung Cancer Is Correlated with Markers of Hypoxia/Acidity and with Poor Prognosis of Patients. MI Koukourakis A Giatromanolaki RA Brekken E Sivridis KC Gatter AL Harris EH Sage, Cancer Res 2003 63 5376 80 14500371
24. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. GK Yiu WY Chan SW Ng PS Chan KK Cheung RS Berkowitz SC Mok, Am J Pathol 2001 159 609 22 11485919
25. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. G Watkins A Douglas-Jones R Bryce RE Mansel WG Jiang, Prostaglandins Leukot Essent Fatty Acids 2005 72 267 72 10.1016/j.plefa.2004.12.003 15763438
26. Frequent inactivation of SPARC by promoter hyperme thylation in colon cancers. E Yang HJ Kang KH Koh H Rhee NK Kim H Kim, Int J Cancer 2007 121 567 75 10.1002/ijc.22706 17397030
27. Aberrant methylation of SPARC in human lung cancers. M Suzuki C Hao T Takahashi H Shigematsu N Shivapurkar UG Sathyanarayana T Iizasa T Fujisawa K Hiroshima AF Gazdar, Br J Cancer 2005 92 942 8 10.1038/sj.bjc.6602376 15756262
28. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor stromal interactions. N Sato N Fukushima N Maehara H Matsubayashi J Koopmann GH Su RH Hruban M Goggins, Oncogene 2003 22 5021 30 10.1038/sj.onc.1206807 12902985
29. SPARC, a matricellular glycoprotein with important biological functions. Q Yan EH Sage, J Histochem Cytochem 1999 47 1495 506 10567433
30. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. A Chlenski S Liu LJ Guerrero Q Yang Y Tian HR Salwen P Zage SL Cohn, Int J Cancer 2006 118 310 6 10.1002/ijc.21357 16052522
31. SPARC deficiency leads to early-onset cataractogenesis. K Norose JI Clark NA Syed A Basu E Heber-Katz EH Sage CC Howe, Invest Ophthalmol Vis Sci 1998 39 2674 80 9856777
32. Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. E Jendraschak EH Sage, Semin Cancer Biol 1996 7 139 46 10.1006/scbi.1996.0019 8773299
33. SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. C Kupprion K Motamed EH Sage, J Biol Chem 1998 273 29635 40 10.1074/jbc.273.45.29635 9792673
34. SPARC induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. CK Yunker W Golembieski N Lemke CR Schultz S Cazacu C Brodie SA Rempel, Int J Cancer 2008 122 2735 43 10.1002/ijc.23450 18350569
35. SPARC is a key Schwannian derived inhibitor controlling neuroblastoma tumor angiogenesis. A Chlenski S Liu SE Crawford OV Volpert GH DeVries A Evangelista Q Yang HR Salwen R Farrer J Bray SL Cohn, Cancer Res 2002 62 7357 63 12499280
36. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. MJ Tang IT Tai, J Biol Chem 2007 282 34457 67 10.1074/jbc.M704459200 17897953